Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Corcept Therapeutics Incorporated (CORT) reported revenue of $165M in Q1 2026 (quarter ended March 31, 2026), up 4.9% from the same quarter a year earlier. That came with a gross margin of 98% and net loss of $32M. For the full year FY2025, revenue was $761M (+13% year on year) and net income $100M.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.